Therapy (HCV)

Study Will Look at Affects of Long-Term Antiviral Therapy in Hepatitis C Patients

Published in Hepatitis Weekly, August 14th, 2000

The University of Michigan Health System is one of a select group of clinical centers launching a new study for patients with chronic hepatitis C. The study - the longest and largest ever for hepatitis C - will examine the effects of long-term antiviral therapy in potentially slowing or halting the progression of liver disease.

Four million Americans are infected with the hepatitis C virus. It's estimated that 20% of those patients will eventually develop cirrhosis, liver failure, or liver cancer. More than half of all hepatitis C patients will not respond to current treatment.

"The aim is to identify patients with very advanced liver disease...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-08-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry